Relevium Acquires Exclusive Licence
From California Based Cannakids®
MONTREAL, Canada -- May 30, 2019 -- InvestorsHub NewsWire
-- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “Company” or
“Relevium”), is pleased to announce that its wholly owned
subsidiary Biocannabix Health Corporation Inc., has completed
necessary compliance process and obligations for the acquisition
for exclusive licensing with cannabis company Cannakids®.
The Company’s Pediatric Cannabinoid Strategy
Biocannabix Health Corporation, a wholly-owned subsidiary of
Relevium is focusing on delivering all the potential health
benefits of cannabinoid formulations in full compliance of the
legal and regulatory framework to Pediatric patients in Canada. The
company will focus initially on nutraceutical formulations aimed at
behavioral and developmental conditions including ADHD and
Hyperactivity amongst others. The Company’s initial focus will be
on education, compliance, branding and developing a fully auditable
supply chain of Cannakids products nationwide.
Aurelio Useche, CEO stated: “According to
Tecnavio2018, the global pediatric market for medicines will reach
121 billion by 2021 and we intend to lead the way in Endo-Medicinal
Nutraceuticals.” Mr. Useche stated further: “We are delighted to
have completed this lengthy process and very keen to start working
towards building the pathway to the full commercialization of
Pediatric Endo-Medicinal Nutraceuticals in partnership with
Cannakids®.”
Biocannabix and the Exclusive Cannakids®
License
On December 13, 2019 the Company announced it had renegotiated and
restructured the original investment transaction in favour of an
exclusive license of intellectual property, including formulations,
SOPs and patient data for pediatric applications for the Canadian
market. Under the exclusive licence agreement, Relevium has made an
initial investment of CAD$1.3 Million through the issue of
11,911,111 shares and CAD$200,000 in cash.
The licensing agreement between Biocannabix and
Cannakids® grants the exclusive Canadian rights to the CannaKids IP
including formulations, SOPs, dosing, titration and patient data
with a Royalty on sales of 13%.
Tracy Ryan, CEO of Cannakids®, stated: “The
Cannakids team is ecstatic to now be extending our reach into
Canada. It has always been our goal to help patients on a global
scale, and we are proud to have Relevium as our Canadian partner to
help us take that next step in making our dreams a reality. We look
forward to helping Canadians find holistic relief from their
ailments, all while working towards expanding our research to
patients both, young and old.”
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the Health and Wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec,
is a biopharma nutraceutical company focused on delivering
pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
About Cannakids®
CannaKids.org is a privately held company that has provided CO2
extracted, lab tested cannabis oil products to thousands of
patients over the past 4 years. Using nurse guided assistance, the
brand has been synonymous with some of the most recognized patient
success stories in the world. Catering to Patients of All Ages,
Cannakids employs medical experts with dosing expertise that span
across hundreds of ailments. The Company has indication specific
formulations backed by anecdotal, in-house patient data, recent
research, and medical findings from their partners at the Technion
Institute in Israel.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Cautionary Note Regarding Forward-Looking
Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM
TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Aug 2023 to Aug 2024